Biotechnology industry analysis: EL7 Score and the best stocks ranked by value, profitability, and momentum.
128 of 152
P/E 14.2 vs period average 14.3 Near its historical average
Ranked among 204 stocks with a market cap above $500M. Smaller companies are excluded from the ranking.
Rank | Company | Price | P/E | Value | Growth | Quality | EL7 Score |
|---|---|---|---|---|---|---|---|
| 1/204 | ![]() | $31.55 | 3.3 | 91 | 78 | 98 | 100 |
| 2/204 | ![]() | $49.63 | 3.0 | 93 | 69 | 98 | 100 |
| 3/204 | ![]() | $115.85 | 14.4 | 85 | 64 | 93 | 99 |
| 4/204 | ![]() | $65.41 | 20.5 | 74 | 65 | 97 | 99 |
| 5/204 | ![]() | $17.16 | 7.4 | 84 | 73 | 86 | 99 |
| 6/204 | ![]() | $144.79 | 21.4 | 77 | 76 | 95 | 98 |
| 7/204 | ![]() | $810.69 | 20.0 | 76 | 31 | 84 | 98 |
| 8/204 | ![]() | $37.40 | 12.0 | 92 | 52 | 86 | 98 |
| 9/204 | ![]() | $72.68 | 62.7 | 40 | 49 | 82 | 97 |
| 10/204 | ![]() | $20.89 | 4.8 | 94 | 66 | 72 | 96 |
Score = market-cap-weighted percentile rank of the sector stocks vs the whole market (0-100). Higher = stronger.
Score = market-cap-weighted percentile rank of the sector stocks vs the whole market (0-100). Higher = stronger.
Insider purchases in the sector's stocks
Funds that track the sector and each fund's exposure to it.
Fund | Exposure | Assets | Expense |
|---|---|---|---|
| IBBiShares Biotechnology ETF | 100.0% | $11B | 0.44% |
| VHTVanguard Health Care ETF | 100.0% | $22B | 0.09% |
| IHIiShares U.S. Medical Devices ETF | 99.7% | $4B | 0.37% |
| XLVState Street Health Care Select Sector SPDR ETF | 99.1% | $47B | 0.08% |
The percentage is the sector's share of the fund's assets, per the latest available data.
Upgrades and downgrades on the sector's stocks